Molecular Partners AG is a clinical-stage biotech company. It involved in developing a new class of custom-built protein drugs known as DARPin(R) therapeutics. Molecular Partners AG is based in SWITZERLAND.
| Revenue (Most Recent Fiscal Year) | $5.65M |
| Net Income (Most Recent Fiscal Year) | $-61.39M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 21.24 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.01 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -2681.69% |
| Net Margin (Trailing 12 Months) | -1043.01% |
| Return on Equity (Trailing 12 Months) | -42.20% |
| Return on Assets (Trailing 12 Months) | -38.12% |
| Current Ratio (Most Recent Fiscal Quarter) | 15.28 |
| Quick Ratio (Most Recent Fiscal Quarter) | 15.28 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.53 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.50 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.81 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.92 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 40.38M |
| Free Float | 37.98M |
| Market Capitalization | $144.44M |
| Average Volume (Last 20 Days) | 3069.10 |
| Beta (Past 60 Months) | 1.15 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 5.93% |
| Percentage Held By Institutions (Latest 13F Reports) | 26.55% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |